Hodgkin Lymphoma and Aggressive non-Hodgkin Lymphoma

Clinical trials for patients with Hodgkin Lymphoma or non-Hodgkin Lymphoma. This group of cancer affects a type of white blood cell that plays an important role in the immune system.

If you would like to be considered for a clinical trial you will require a referral from your current treating team. Visit the Joining a Clinical Trial page for referral information. 

For more information on clinical trials, get in contact with our cancer clinical trials enquiry coordinator.

Clinical Trials Enquiry Coordinator

Business hours, Mon to Friday between 9am - 2pm
Email [email protected]
Phone (03) 8559 7456

Open and Recruiting Clinical Trials

A clinical trial to safety and effectiveness of new treatment NP30179 given alone or in combination with Obinituzumab in patients with B-cell non-Hodgkin’s lymphomas.

Cancer type

B-cell non-Hodgkin’s lymphomas – follicular lymphoma (FL), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), diffuse large B cell lymphoma (DLBCL), primary mediastinal B cell lymphoma (PMBCL) including patients who show Richter’s transformation.

Status

Open and recruiting

Phase

One: A phase one clinical trial tests new treatments sometimes for the first time in humans, usually in a small group of patients. The aim of a phase one is to test the safety of the new treatment and find the best dose to give patients.

Brief summary

The purpose of this clinical trial is to find the best dose of a new treatment RO7082859, given alone or in combination with Obinituzumab and how effective it is on certain cancers. The treatment RO7082859 is a T-cell bispecific antibody which works by activating or supporting the body’s own immune system to identify and kill cancer cells. Obinituzaumab is an antibody that targets the lymphoma cells. The drugs are given intravenously .

Who can participate

Patients who:

  • Have had the cancer return or not respond to at least two previous regimes of treatment, at least one including  a drug such as Rituximab

Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.

A clinical trial to test the safety and effectiveness of treatment RO7227166 given with Obinituzumab or RO708259 in patients with B-cell non-Hodgkin’s lymphomas

Cancer type

B-cell non-Hodgkin’s lymphoma - Follicular lymphoma (FL), marginal zone lymphoma, mantle cell lymphoma, diffuse large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma (PMBCL), transformed follicular lymphoma and Richter’s transformation.

Status

Open and recruiting

Phase

One: A phase one clinical trial tests new treatments sometimes for the first time in humans, usually in a small group of patients. The aim of a phase one is to test the safety of the new treatment and find the best dose to give patients.

Brief summary

The purpose of this clinical trial is to best dose of a new treatment RO70227166 given with either Obinituzumab or RO7082859 and how effective it is on certain cancers. Treatment is given intravenously (through a needle in your arm).

Who can participate

Patients who:

  • Have had the cancer return or not respond to at least two previous treatments
  • Have at least one measurable lesion from the disease either by CT scan or PET scan
  • Have not had an allogeneic bone marrow Transplant

Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.

A clinical trial to compare treatment Tisagenlecleucel, a CAR-T cell therapy,  to the treatment standardly given to patients with aggressive B-cell non-Hodgkin lymphoma

Cancer Type

Aggressive B-cell non-Hodgkin lymphoma

Status

Open and recruiting

Phase

Three: A phase three clinical trial follows a phase two, in a larger group of patients with specific cancer types. The aim of a phase three is to compare the new treatment to what is available for that cancer type.

Brief summary

A clinical trial to compare  the safety and effectiveness of treatment Tisagenlecleucel to the treatment standardly given to patients with aggressive B-cell non-Hodgkin lymphoma. Patients will be given one of the following:

  • Tisagenlecleucel after optional chemotherapy
  • Standard of care chemotherapy followed by stem cell transplant
Who can participate

Patients who:

  • Have had their first regime of treatment and are in partial remission
  • Have had their cancer return after treatment, including the return of disease within a year their final cycle of treatment that included an anti CD20 antibody ( such as Rituximab) and chemotherapy
  • Are suitable for an autologous transplant

Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.

A clinical trial to test the safety and effectiveness of immunotherapy Pembrolizumab as a first treatment option for patients with Hodgkin Lymphoma who are considered unsuitable for chemotherapy

Cancer Type

Hodgkin Lymphoma

Status

Open and recruiting

Phase

Two: A phase two clinical trial follows a phase one, in a large group of patients with selected cancer types. The aim of a phase two is to find out if the new treatment is effective in these cancer types.

Brief summary

A study to assess if Pembrolizumab is an effective treatment in Hodgkin lymphoma patients when they are unable to receive standard chemotherapy. Patients will be given Pembrolizumab intravenously (through a needle in your arm) every 3 weeks.

Who can participate

Patients who:

  • Are not eligible for chemotherapy as a first treatment option

Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.

A clinical trial of treatment Brentuximab Vedotin given with donor lymphocyte infusion directed through PET scan therapy for patients with Hodgkin lymphoma

Cancer Type

Hodgkin lymphoma

Status

Open and recruiting

Phase

One / two: A phase one / two clinical trial combines a phase one and two. The phase one tests new treatments sometimes for the first time in humans, usually in a small group of patients. The phase two part tests the new treatment in a larger group of patients with selected cancer types. The aim of a phase one / two is to find the best dose of the new treatment and see if it works against the cancer.

Brief summary

A clinical trial which uses the treatment Brentuximab Vedotin given with donor lymphocytes (type of white blood cell, found in the immune system and collected from the same donor who provided the cells for the original transplant) in patients with Hodgkin’s Lymphoma that has persisted after an allogeneic stem cell transplant. The results of PET scans are used to determine when to commence the brentuximab.

Who can participate

Patients who:

  • Have Hodgkin lymphoma that persists after an allogeneic bone marrow transplant

Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.

A clinical trial to test the safety and effectiveness of Lenalidomide given with Venetoclax and Obinituzumab in patients with Follicular Lymphoma that has not been previously treated

Cancer Type

Follicular Lymphoma

Status

Open and recruiting

Phase

One / two: A phase one / two clinical trial combines a phase one and two. The phase one tests new treatments sometimes for the first time in humans, usually in a small group of patients. The phase two part tests the new treatment in a larger group of patients with selected cancer types. The aim of a phase one / two is to find the best dose of the new treatment and see if it works against the cancer.

Brief summary

A clinical trial to find the best dose of Venetoclax ,when combined with lenolidomide and Obinituzumab in patients with Follicular Lymphoma and to find out how effective this combination of treatment is. Lenalidomide and Venetoclax are taken orally, Obinituzumab is given intravenously (through a needle in your arm) together in cycles, 12 cycles in total.

Who can participate

Patients who:

  • Have Follicular Lymphoma and not yet received any treatment(treatment-Naïve)

Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.